Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Journal of Clinical Medicine|March 17, 2025
Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM)Ivan Krecak, Marko Lucijanic, Rajko KusecClinical Advances in Hematology & Oncology : H&O|November 10, 2023
Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasmsIvan Krecak, Srdan Verstovsek, Marko LucijanicIndian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|February 23, 2026
Impact of Angiotensin-Converting Enzyme Inhibitors on Disease Symptoms in Patients with Chronic Myeloproliferative NeoplasmsHrvoje Holik, Marko Lucijanic, Ivan KrecakCurrent Hematologic Malignancy Reports|August 6, 2022
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential ThrombocythemiaIvan Krecak, Marko Lucijanic, Srdan VerstovsekExpert Review of Hematology|April 1, 2023
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia veraIvan Krecak, Marko Skelin, Srdan VerstovsekAnnals of Hematology|September 4, 2023
Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectivesIvan Krecak, Srdan Verstovsek, Marko LucijanicJournal of Psychopharmacology (Oxford, England)|March 14, 2024
Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir useIvan Papic, Petra Bistrovic, Ivan Krecak, et al.Pharmacology|July 31, 2024
Negative Prognostic Associations of Selective Serotonin Reuptake Inhibitors Use in Hospitalized COVID-19 Patients and Potential Contribution of Cardiovascular ComorbiditiesIvan Papic, Petra Bistrovic, Ivan Krecak, et al.Biomedicines|January 25, 2025
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?Davor Galusic, Ivan Krecak, Viktor Blaslov, et al.Expert Review of Hematology|June 16, 2025
Thrombo-vera: a new thrombosis risk model for polycythemia vera using modern variable selection methodsIsidora Arsenovic, Natasa Milic, Nikola Grubor, et al.Pageof 3